ENOA:F:F-BNP Paribas Easy - MSCI North America ex Controversial Weapons (EUR)

ETF | Others |

Last Closing

USD 23.195

Change

-0.16 (-0.66)%

Market Cap

N/A

Volume

N/A

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-30 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

+0.08 (+0.30%)

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.05 (-0.09%)

USD 115.53B
SXR8:F iShares Core S&P 500 UCITS ETF..

N/A

USD 96.59B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 94.63B
SXRZ:F iShares VII PLC - iShares Nikk..

N/A

USD 57.94B
XDNY:F Xtrackers MSCI Japan ESG Scree..

N/A

USD 54.05B
VUAA:F Vanguard S&P 500 UCITS Acc

-0.07 (-0.07%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

+0.18 (+0.19%)

USD 51.63B
XJSE:F Xtrackers II - Japan Governmen..

+0.08 (+1.07%)

USD 40.74B
0ZC:F Zscaler Inc

-3.10 (-2.00%)

USD 37.92B

ETFs Containing ENOA:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 16.66% 78% C+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 16.66% 75% C 62% D
Trailing 12 Months  
Capital Gain 25.90% 80% B- 73% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 25.90% 77% C+ 64% D
Trailing 5 Years  
Capital Gain 97.88% 95% A 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.88% 95% A 73% C
Average Annual (5 Year Horizon)  
Capital Gain 14.98% N/A N/A 78% C+
Dividend Return 14.98% N/A N/A 71% C-
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 15.23% N/A N/A 76% C+
Risk Adjusted Return 98.35% N/A N/A 95% A
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:

There is nothing we particularly dislike